drugset / Trial / NCT05561062

Atorvastatin in Patients With Ulcerative Colitis

NCT05561062

Phase 2 Completed 50 enrolled Tanta University
RandomizedParallel-groupDouble-blindTreatment

Summary

Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease characterized by diffused inflammation of the colon and rectum mucosa; however, the exact underlying mechanisms of UC remain poorly understood. Statins exert numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement, and immunomodulation independent of their basic lipid-lowering property.

Timeline

Start
2022-12-01
Primary completion
2024-11-01
Completion
2024-11-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule 80 mg